InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 3,858 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 3,858 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $2.71, for a total value of $10,455.18. Following the completion of the sale, the insider owned 1,135,319 shares in the company, valued at approximately $3,076,714.49. This represents a 0.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Stock Performance

Shares of NYSE:NSPR opened at $1.03 on Friday. The business’s fifty day moving average price is $1.39 and its two-hundred day moving average price is $1.67. The stock has a market cap of $48.24 million, a PE ratio of -1.37 and a beta of 0.82. InspireMD, Inc. has a one year low of $0.97 and a one year high of $2.93.

Trending Headlines about InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: There were no clearly positive company-specific announcements in the latest items, so investor attention is centered on the stock’s low valuation and recent trading near its 1-year low. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The most recent insider sale was small and attributed to tax withholding obligations tied to equity award vesting, which often makes the transactions less concerning than open-market selling. Multiple similar sales were also reported earlier this year. SEC filing
• Negative Sentiment: Repeated insider sales can still weigh on sentiment, as investors may view them as a sign of limited near-term upside or a lack of conviction from management, especially for a small-cap stock already trading below its recent moving averages. SEC filing

Analyst Upgrades and Downgrades

A number of brokerages have commented on NSPR. Piper Sandler reiterated an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Loop Capital set a $5.00 target price on InspireMD in a report on Tuesday, February 24th. Maxim Group began coverage on InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 target price on the stock. Finally, Lake Street Capital set a $4.00 target price on InspireMD in a report on Monday, May 4th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $4.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Ghisallo Capital Management LLC purchased a new position in shares of InspireMD during the 3rd quarter worth $2,221,000. Aberdeen Group plc purchased a new position in shares of InspireMD during the 3rd quarter worth $5,979,000. Rosalind Advisors Inc. lifted its stake in shares of InspireMD by 70.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the period. Creative Planning purchased a new position in shares of InspireMD during the 2nd quarter worth $44,000. Finally, Virtu Financial LLC purchased a new position in shares of InspireMD during the 4th quarter worth $31,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.